Page 2 - Quantitative Understanding News Today

New Long-Term Data from FOREST-HCM, the Open-Label Extension Study of Aficamten,Show Sustained Improvements in Clinical Efficacy Endpointsand No Treatment Interruptions for Low Ejection Fraction ...

Cytokinetics, Incorporated announced that the baseline characteristics of patients randomized in SEQUOIA-HCM , the pivotal Phase 3 clinical trial of aficamten in patients with symptomatic obstructive...

SOUTH SAN FRANCISCO, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that ACACIA-HCM (Assessment Comparing Aficamten to Placebo on Cardiac Endpoints In Adults with Non-Obstructive

First Phase 3 Trial Evaluating Monotherapy with a Cardiac Myosin Inhibitor Compared to Monotherapy with a Beta Blocker in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy SOUTH SAN... | June 20, 2023

Two Late Breaking Clinical Trials Sessions to Feature New Data from REDWOOD-HCM OLE...

Initial Data from REDWOOD-HCM OLE, the Open Label Extension Study of Aficamten, to be Presented at Heart Failure 2022 on May 23, 2022 Continued Launch...

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Go-To-Market Strategy Focuses on Educating Healthcare Professionals, Ensuring Managed Care Access, and Enacting Programs for Patient Access, Education and...

A cutting-edge digital tool that will make it cheaper, safer and faster for pharmaceutical companies to predict protein stability - a vital step in the development of new medicines - is being rolled out by scientists from the UK's University of Bath through their spin-out company, BLOC Labs.

A digital tool that will make it cheaper, safer and faster to develop new medicines is being rolled out by scientists from the University of Bath in the UK.